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Abstract
Treatment modalities of chronic plaque psoriasis have dramatically changed over the past ten years with a still
continuing shift from inpatient to outpatient treatment. This development is mainly caused by outpatient availability of
highly efficient and relatively well-tolerated systemic treatments, in particular BioLogicals. In addition, inpatient
treatment is time- and cost-intense, conflicting with the actual burst of health expenses and with patient preferences.
Nevertheless, inpatient treatment with dithranol and UV light still is a major mainstay of psoriasis treatment in
Germany. The current study aims at comparing the total costs of inpatient treatment and outpatient follow-up to mere
outpatient therapy with different modalities (topical treatment, phototherapy, classic systemic therapy or BioLogicals)
over a period of 12 months. To this end, a retrospective cost-of-illness study was conducted on 120 patients treated
at the University Medical Centre Mannheim between 2005 and 2006. Inpatient therapy caused significantly higher
direct medical, indirect and total annual costs than outpatient treatment (13,042 € versus 2,984 €). Its strong
influence on cost levels was confirmed by regression analysis, with total costs rising by 104.3% in case of inpatient
treatment. Patients receiving BioLogicals produced the overall highest costs, whereas outpatient treatment with
classic systemic antipsoriatic medications was less cost-intense than other alternatives.
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Introduction
Psoriasis is a chronic inflammatory disease affecting about
2% of the population in Europe and Northern America. In
Germany, an estimated 1.6 million individuals suffer from this
disease that implicates considerable physical, psychological
and social burden for patients but also a major financial burden
for health economy [1,2]. Annual costs for psoriasis treatment
come up to 7 billion € in Germany and up to 11 billion US-$ in
the United States [3–6]. In the US, moderate to severe
psoriasis is mostly treated in an outpatient setting [7,8], while in
Germany and other European countries inpatient treatment,
mostly conducted as a regimen of topical dithranol combined
with UV light, still is a common, but expensive therapeutic
alternative [9–12]. However, this regimen is increasingly being
replaced by highly effective outpatient alternatives, in particular
by biologicals [4,13–16].
Given the rising expenses for health, economic analyses
comparing the different treatment modalities are imperative.
Such analyses performed in the Angloamerican context mostly
concentrated on cost efficiency of different outpatient
alternatives [5,17–19], as inpatient therapy does not play a
major role in these regions. During the last years some
European studies have examined costs for psoriasis treatment
including inpatient therapy in detail [14,20–26]. However, they
often do not consider inpatient therapy as a separate treatment
alternative to be compared with outpatient therapy or they only
include selected outpatient treatments. Comprehensive cost
analyses considering the available treatment options for
outpatients in comparison to inpatients are lacking so far. We
therefore initiated this study to compare inpatient therapy with
all available outpatient treatments from an economic point of
view.
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Materials and Methods
Data collection
The present cost-of-illness analysis was carried out as a 12-
month retrospective bottom-up study with a separate view of
inpatient and outpatient therapy. Three hundred ninety-one
patients treated for psoriasis between January 2005 and July
2006 either as inpatients or outpatients at the Department of
Dermatology of the University Medical Centre Mannheim,
University of Heidelberg, were contacted by mail in December
2006. Of 202 patients answering back (return rate: 51.7%), 149
gave written informed consent to participate. One hundred
twenty patients were available for personal interviews and
could be included in the study. The personal interview was
conducted by one interviewer from February until July 2007
using a 17-page standardized questionnaire (see
Questionnaire S1), focussing on sociodemographic
characteristics (age, sex, annual income, employment status,
weekly working hours, insurance), treatments received for
psoriasis (in- or outpatient therapy, treatment mode, duration,
frequency and location, number of clinic or office visits,
diagnostic procedures, kind and number of prescriptions,
package sizes), individual treatment costs (co-payments for
prescriptions, costs for therapies not covered by the insurance
including skin care products and private treatments at health
resorts, transportation expenses) as well as days absent from
work due to psoriasis. Moreover, detailed information on
duration and frequency of in- and outpatient treatment and
visits, prescribed treatments, diagnostic procedures and sick
certificates was collected from the medical records, together
with medical information such as Psoriasis Area and Severity
Index (PASI), Dermatology Life Quality Index (DLQI), presence
or absence of psoriatic arthritis and co-morbidities. Disease
severity was classified using the maximal PASI recorded in the
investigation period in conjunction with the classification criteria
of the Committee for Medicinal Products for Human Use
(CHMP; 1). For individuals treated merely as outpatients, costs
and medical details were assessed for a 12-month period
between January 2005 and July 2006. For inpatients,
corresponding data were collected for the months following
hospital demission during outpatient care.
Ethics statement
The study was conducted according to the ethics principles
expressed in the Declaration of Helsinki and approved by the
Medical Ethics Committee II of the University Medical Centre
Mannheim, University of Heidelberg, Mannheim, Germany. All
patients gave written informed consent for participation in the
study.
Sample stratification
For statistical analysis the cohort (n=120 patients) was
stratified into inpatients and outpatients as well as according to
the most intense outpatient treatment modality, i.e. topical
therapy, phototherapy (PUVA, narrowband UVB 311 nm,
selective UV therapy), classic systemic therapy (methotrexate,
fumaric acid, cyclosporine, retinoids) or biological therapy
(infliximab, etanercept or efalizumab). The majority of patients
(68%) received a combination of two or more treatment
modalities (for details, see Table 1). For example, in the group
“classic systemic therapy” 9 of 12 outpatients were prescribed
topical treatment in addition to a classic systemic agent and
one patient was treated with a triple combination of classic
systemic medication, topical therapy and phototherapy.
Seventy-one individuals were treated merely as outpatients,
with 28 receiving topical therapy, 28 phototherapy, 12 classic
systemic therapy and 3 biologicals as most intense therapy.
Forty-nine patients were admitted as inpatients at least once
during the observation period. In the year following inpatient
treatment eight patients received only topical therapy, 21
phototherapy, 15 classic systemic therapy and 5 biologicals as
most intense treatment (Table 1).
Table 1. Sample stratification according to the most intense outpatient treatment.
Grouping by maximal outpatient therapy Inpatients (n=49) Outpatients (n=71)
Topical therapy 8 (16.3%) 28 (39.4%)
Phototherapy 21 (42.9%) 28 (39.4%)
Phototherapy only 1 0
Phototherapy + topical therapy 20 28
Classic systemic therapy 15 (30.6%) 12 (16.9%)
Classic systemic therapy only 0 2
Classic systemic therapy + topical therapy 9 9
Classic systemic therapy + phototherapy + topical therapy 6 1
Biological therapy 5 (10.2%) 3 (4.2%)
Biological therapy only 0 0
Biological therapy + topical therapy 3 2
Biological therapy + classic systemic therapy 1 0
Biological therapy + classic systemic therapy + topical therapy 1 0
Biological therapy + classic systemic therapy + phototherapy + topical therapy 0 1
doi: 10.1371/journal.pone.0078152.t001
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Cost definition and calculation
Costs were classified into direct medical, direct non-medical
and indirect costs, according to economic analyses from the
societal perspective [27]. Direct medical costs were costs for
inpatient treatment, outpatient medication, consultation and
diagnostics as well as for skin care products. These costs were
assessed according to DRG (“Diagnosis Related Groups”) and
EBM (”Einheitlicher Bewertungsmaßstab”, Uniform Value
Scale) guidelines valuable in 2006 as well as to the valid
medication prices in Germany (as referenced in the “Red List”).
Direct non-medical costs included costs for travel expenses or
for private treatments at health resorts. These costs were
directly generated from the personal interview. Indirect costs,
accruing from loss of working time, were estimated from the
mean gross income of the individual subject according to the
human capital approach. The human capital approach is one of
the most frequently used methods for estimating indirect costs
through loss of working time. As one major advantage, e.g. in
contrast to the friction cost approach, the human capital
approach assigns losses of reduced honorary activities caused
by illness an equal monetary value.
Statistical analysis
Data were analyzed using SPSS 12.0 and Microsoft Office
Excel 2003 with t-tests, variance analysis (ANOVA, Welch,
Brown-Forsythe) and multivariate regression analysis. In the
latter, logarithmic values for direct medical costs, costs for
outpatient medication, costs for outpatient visits and
diagnostics, indirect costs through loss of working time and
total costs were taken as dependent variables. After logarithmic
transformation Kolmogoroff-Smirnoff tests presented normal
distribution of all cost variables (Table S1). Logarithmic
calculus is a well-known approach for variables which cannot
take values <0. Besides, it allows comprehensive interpretation
of regression results, as interpretation of point estimates as
changes in percent or percentage points is only possible with
logarithmic dependent variables.
Independent variables were age, sex, income, employment
status, PASI, DLQI and disease duration. Dummy variables for
inpatient therapy (reference group: outpatient therapy), for
phototherapy and systemic therapy (reference group: topical
therapy) as well as for full time employment, part time
employment and minor employment (reference group: not
working) were incorporated. All independent variables were
concomitantly integrated into the analysis.
Results
Demographic and clinical characteristics
Among the patients included into the study, 55% were male
and 45% female (Table 2). The mean age was 51.8 years.
Forty percent of the patients worked full time (>37.5 hours per
week) and 13.3% part time (19.5-37.5 hours per week)
whereas 40% had no employment at all because of retirement
(25.8%), unemployment (9,2%) or homemaking (8,3%). The
vast majority had compulsory health insurance.
Ninety percent of the patients suffered from plaque psoriasis,
and the mean disease duration was 22 years. Mean PASI
scores were 13.5 for inpatients and 8.9 for mere outpatients.
According to the classification criteria of the Committee for
Medicinal Products for Human Use [1], more than 70% suffered
from moderate or severe psoriasis (Table 2).
When inpatients were compared to outpatients, the former
had a longer disease duration with an earlier onset, more
severe psoriasis (as assessed by PASI, p=0.002, t-test) and a
higher impact on life quality as assessed by DLQI (t-test, not
significant).
Inpatients were absent from work for more than one month
during the assessment period whereas mere outpatients only
lost two working days due to psoriasis (Table 2; p<0.001, t-
test). After demission from hospital former inpatients sought
medical consultation for psoriasis somewhat more frequently
than mere outpatients (12.7 versus 9.5 consultations per year,
t-test, not significant).
In case of inpatient treatment, the mean length of a single
hospital stay at our department was 19.6 days. A considerable
number of patients (26.5%) required more than one hospital
stay during the 12-month observation period leading to a mean
total hospitalization time of 27.9 days. Eighty-four percent of
inpatients were treated with dithranol and phototherapy. Mean
patient-reported remission time after inpatient treatment was
104.3 days. Remarkably, despite intense topical and
phototherapy during the hospital stay a high percentage of
inpatients required phototherapy (55%), classic systemic
therapy (35%) or biologicals (10%) after demission.
Regarding the different treatment modalities prescribed in an
outpatient setting, either for mere outpatients or as follow-up
therapy after inpatient treatment, 93% of all patients were
treated with topical therapy, including medical skin care
products, 45% with phototherapy, 25% with classic systemic
therapy and 6.7% with biologicals. Details of the different
regimens are indicated in Table 3. In 68% of all patients a
combination of different treatment modalities was
recommended, most frequently a combination of phototherapy
or classic systemic therapy with topical therapy (Table 1).
Cost analysis of the whole collective
When costs were analyzed for the whole patient collective,
mean total annual costs per patient added up to 7,092 €,
including average direct medical costs of 4,978 €, direct non-
medical costs of five hundred and ninety-eight € and indirect
costs through loss of working time of 1,515 € (Table 4). In the
category of direct medical costs inpatient treatment accounted
for the highest expenses (2,311 € per patient and year, 46.4%
of all direct medical costs), followed by expenses for outpatient
medication (1,987 €, 39.9%). In contrast, costs for outpatient
visits and diagnostics as well as costs for skin care were
comparatively low.
Cost comparison between inpatients and outpatients
For further cost analysis and comparison the cohort was
stratified into inpatients and outpatients. Total annual costs for
inpatients were more than as fourfold high as those for mere
outpatients (Table 4; 13,042 € versus 2,985 €; p<0.001, t-test).
This was due to (a) higher total direct medical costs including
costs for hospitalization (9,511 € vs. 1,851 €; p<0.001, t-test)
Cost-of-Illness in Psoriasis
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and (b) higher indirect costs through loss of working time
(2,973 € vs. five hundred and nine €; p<0.001, t-test).
Unexpectedly, however, costs for outpatient medication in the
time following hospitalization were also significantly higher for
former inpatients than for mere outpatients (3,078 € vs. 1,234
€; p=0.026, t-test), leading to more than twofold higher direct
medical costs for ambulatory treatment (3,850 € versus 1,850
€; p=0.021, t-test).
Cost comparison according to different treatment
modalities
Stratification according to the different treatment modalities
(topical therapy, phototherapy, classic systemic therapy,
biologicals, Tables 5 and 6) revealed that patients receiving
biologicals as most intense treatment produced several fold
higher total annual costs than patients treated with all other
modalities, both in the inpatient (30,200 €; Table 5) and in the
outpatient group (11,601 €; Table 6). This was mainly
attributable to high medication costs. In addition, therapy with
biologicals appeared to be associated with considerably higher
indirect costs due to loss of working time (Tables 5 and 6). The
latter may at least partially be explained by the application of
infliximab in 3 of 8 patients that needs to be delivered as
infusion in an office- or clinic-based setting. However, because
of the small number of patients receiving biologicals (n=5 in the
inpatient and n=3 in the outpatient cohort), statistical
significances could not be calculated for this subgroup.
Both in the inpatient and in the outpatient group, classic
systemic therapy produced significantly higher direct medical
costs in the outpatient sector than topical or phototherapy
(3,124 € resp. 2,223 €, p<0.001, t-tests; Tables 5 and 6). This
was attributable both to significantly higher expenses for
outpatient visits and diagnostics (three hundred and fifty-eight €
resp. three hundred and seventeen €, p<0.001, t-tests; Tables
5 and 6) and to significantly higher costs for outpatient
medication (2,233 € resp. 1,557 €, p=0.006 for the inpatient
group, p=0.015 for the mere outpatient group, t-tests).
Direct non-medical costs, including e.g. costs for private
treatments at health resorts or travel expenses, were
somewhat higher for outpatients on topical therapy than for
those on phototherapy or classic systemic therapy (1,121 € vs.
three hundred and forty-seven € vs. one hundred and ninety-
eight €; Table 6). However, these differences were not
Table 2. Demographic and clinical characteristics of patients included in the study.
 Mean [range]
 All (n=120) Inpatients (n=49) Outpatients (n=71)
Age [years] 51.8 [19-82] 51.5 [25-82] 52.0 [19-79]
Gender m 55%, f 45% m 61%, f 39% m 51%, f 49%
Employment status Full time employment 40% (n=48) 42.9% (n=21) 38% (n=27)
 Part time employment 13.3% (n=16) 8.2% (n=4) 16.9% (n=12)
 Minor employment 6.7% (n=8) 6.1% (n=3) 7% (n=5)
 Unemployment 9.2% (n=11) 14.3% (n=7) 5.6% (n=4)
 Retirement 25.8% (n=31) 22.4% (n=11) 28.2% (n=20)
 Homemaking 8.3% (n=10) 10.2% (n=5) 7.0% (n=5)
Health insurance Compulsory 94.2% (n=113) 93.9% (n=46) 94.4% (n=67)
 Other 5.8% (n=7) 6.1% (n=3) 5.6% (n=4)
Disease duration [years] 22.0 [1-72] 24.8 [1-72] 20.1 [1-57]
Type of psoriasis Psoriasis vulgaris 90% 89.8% 90.1%
 Psoriasis guttata 3.3% 4.1% 0%
 Psoriasis palmoplantaris 6.7% 12.3% 2.8%
PASI Score 10.8 [0-67.2] 13.5 [0-67.2] 8.9 [0.6-34.5]
DLQI Score 9.2 [0-27] 10.2 [0-27] 8.4 [0-26]
Disease severity according to CHMP criteria Light - moderate 29.1% 22.4% 33.8%
 Moderate - severe 26.7% 32.7% 22.5%
 severe 44.2% 44.8% 43.7%
Psoriatic arthritis Established diagnosis 15.8% 20.4% 12.7%
 History of arthralgias 19.2% 14.3% 22.5%
Other comorbidities None 31.7% (n=38) 22,4% (n=11) 38% (n=27)
 1 19.2% (n=23) 22.4% (n=11) 16.9% (n=12)
 2 28.3% (n=34) 26.5% (n=13) 29.6% (n=21)
 >2 20.8% (n=25) 28.7% (n=14) 15.5% (n=11)
Days absent from work due to psoriasis 14.8 32.7 2.4
Outpatient consultations 10.8 12.7 9.5
Time for skin care per week [hours] 4.1 4.9 3.5
Loss of leisure time per week [hours] 6.6 8.8 5.0
doi: 10.1371/journal.pone.0078152.t002
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statistically significant (p=0.174 resp. p=0.102, t-tests).
Furthermore, outpatients receiving phototherapy had higher
indirect costs due to loss of working time than those receiving
topical or systemic therapy (p=0.297 resp. p=0.485, t-tests, not
significant; Table 6).
Overall, the highest cost categories were costs for inpatient
treatment, for outpatient medication and indirect costs for loss
of working time. Remarkably, costs that have to be covered by
the individual, i.e. co-payments for medication, costs for skin
care products and treatments not covered by the insurance as
well as travel expenses were considerable, ranging from four
hundred and forty-four € to 1,944 € per patient per year.
Table 3. Treatment regimens of the patient collective (n=120).
 n [%] of n=120  n [%]
Topical therapy 112 93,3 Vitamin D 88 78,6
   Salicylic acid 66 58,9
   Corticosteroids 62 55,4
   Vitamin D and corticosteroids 57 50,9
   Urea 29 25,9
   Anthralin 28 25,0
   Magistral formulas 18 16,1
   Retinoids 10 8,9
Phototherapy 54 45 Creme- resp. Shower-PUVA 28 51,9
   UVB 311nm 24 44,4
   Light comb 17 31,5
   UVA/UVB 12 22,2
Classic systemic therapy 30 25 Retinoids 10 33,3
   Methotrexate 10 33,3
   Fumaric acid 8 26,7
   Cyclosporine 3 10,0
Biological therapy 8 6,7 Etanercept 3 37,5
   Infliximab 3 37,5
   Efalizumab 2 25,0
doi: 10.1371/journal.pone.0078152.t003
Table 4. Comparison of annual costs for inpatient and outpatient therapy.
 Costs per patient per year [€]
 Mean
 Median [P25, P75]
 All (n=120) Inpatients (n=49) Outpatients (n=71)
Direct medical costs 4,978 9,511 1,851
 2,664 [1,296, 6,164] 6,793 [5,366, 11,061] 1,496 [733, 1,988]
Inpatient therapy 2,311 5,660 -
 0 [0, 4,170] 4,171 [4,114, 8,098] -
Outpatient medication 1,987 3,078 1,234
 850 [446, 1471] 942 [588, 2,666] 757 [335, 1331]
Costs for outpatient visits and diagnostics 210 241 189
 133 [85, 266] 152 [84, 310] 128 [84, 249]
Costs for skin care 470 531 427
 360 [180, 600] 360 [240, 660] 324 [120, 600]
Direct non-medical costs 598 559 625
 101 [24, 579] 96 [26, 551] 108 [24, 654]
Indirect costs 1,515 2,973 509
 0 [0, 2,188] 2,210 [1,217, 3,956] 0 [0, 0]
Total costs 7,092 13,042 2,985
 4,122 [1,508, 10,244] 10,286 [7,153, 16,244] 1,721 [1,038, 3,435]
doi: 10.1371/journal.pone.0078152.t004
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Regression analysis
To analyse the influence of treatment modalities on different
cost categories, we performed a regression analysis (Table 7).
Costs for inpatient therapy were compared to those for mere
outpatient therapy and costs for classic systemic and
phototherapy to those for topical therapy. Due to the small
sample size, patients receiving biologicals had to be excluded
from these analyses (n=112 for regression analysis). Cost
variables were normally distributed according to one-sample
Kolmogoroff-Smirnoff test when using logarithmic values (Table
Table 5. Cost comparison for inpatients stratified according to the maximal follow-up outpatient therapy.
 Costs per patient per year [€]
 Mean
 Median [P25, P75]
 Inpatient therapy (n=49)
 Topical (n=8) Photo (n=21) Systemic (n=15) Biological (n=5)
Direct medical costs 6,189 7,320 9,491 24,083
 5,150 [4,262, 7,896] 5,725 [5,259, 9,641] 7,939 [5,616, 10,518] 23,661 [20,420, 27,958]
Inpatient therapy 5,430 5,411 6,366 4,954
 4171 [3,387, 7305] 4,171 [4,114, 8,163] 4,171 [4,114, 8,098] 4,171 [3,666, 6,633]
Outpatient medication 406 1,206 2,233 17,756
 454 [22, 630] 942 [540, 1,835] 1,316 [757, 3,633] 18,026 [12,952, 22,432]
Costs for outpatient visits and diagnostics 91 122 358 625
 93 [29, 151] 115 [79, 174] 332 [220, 492] 446 [178, 1,154]
Costs for skin care 263 581 533 749
 240 [120, 405] 420 [279, 720] 360 [260, 780] 600 [282, 1,290]
Direct non-medical costs 181 340 853 1,196
 64 [18, 330] 58 [21, 318] 498 [75, 864] 444 [38, 2,729]
Indirect costs 2,141 2,231 3,807 4,921
 1,955 [796, 3,309] 1,877 [549, 3,525] 2,605 [1,658, 4,148] 3,956 [3,213, 7,112]
Total costs 8,512 9,891 14,151 30,200
 6,944 [5,389, 12,478] 8,168 [6,781, 13,615] 10,504 [8,491, 17,511] 26,400 [24,501, 37,798]
doi: 10.1371/journal.pone.0078152.t005
Table 6. Cost comparison for mere outpatients stratified according to their maximal therapy.
 Costs per patient per year [€]
 Mean
 Median [P25, P75]
 Outpatient therapy (n=71)
 Topical (n=28) Photo (n=28) Systemic (n=12) Biological (n=3)
Direct medical costs 1,197 1,509 2,223 9,652
 889 [309, 1,576] 1,519 [1,015, 1,933] 1,942 [1,448, 3,128] 10,785 [6,691, .]
Inpatient therapy - - - -
Outpatient medication 674 860 1,557 8,718
 385 [129, 950] 750 [529, 1,209] 1,329 [822, 2,254] 9,853 [5,679, .]
Costs for outpatient visits and diagnostics 127 153 317 551
 103 [57, 128] 134 [85, 214] 256 [218, 410] 532 [259, .]
Costs for skin care 396 496 349 383
 270 [120, 585] 342 [120, 738] 330 [180, 525] 480 [70, .]
Direct non-medical costs 1,121 347 198 297
 189 [40, 986] 69 [20, 324] 136 [33, 260] 274 [244, .]
Indirect costs 116 958 95 1,651
 0 [0, 0] 0 [0, 0] 0 [0, 0] 182 [0, .]
Total costs 2,434 2,813 2,517 11,601
 1,199 [449, 3,293] 1,655 [1,141, 2,234] 2,160 [1,513, 3,446] 11,706 [11,160, .]
doi: 10.1371/journal.pone.0078152.t006
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S1). Direct medical costs were predicted to rise by 127.8%
(p<0.001) and total costs by 104.3% (p<0.001) if choosing the
inpatient therapy option instead of mere outpatient therapy. By
contrast, costs for outpatient medication, visits and diagnostics
were predicted to decrease by 10.0% or by 31.6%,
respectively, in case of inpatient treatment.
Comparing the influence on cost levels if phototherapy or
classic systemic therapy were chosen instead of mere topical
therapy, all direct medical costs were predicted to rise
significantly (Table 7). The greatest increase was noted for
costs for outpatient medication (103.9%, p<0.001) and costs for
outpatient visits and diagnostics (108.3%, p<0.001) in case of
classic systemic therapy. Indirect costs increased significantly
only in case of phototherapy, as expected from our descriptive
cost analysis. Also in accordance to the descriptive data, total
annual costs raised when phototherapy (30.7%, p=0.030) or
classic systemic therapy (44.1%, p=0.011) were used instead
of mere topical treatment.
Discussion
In the light of rising costs for health care, economic analyses
of treatment strategies are becoming increasingly important.
Several studies have been performed to compare the cost-
effectiveness of selected treatment alternatives for psoriasis,
recently focussing on biologicals [28–30]. Furthermore, trends
in direct medical costs for psoriasis have been analyzed in
detail, comparing UV therapy, classic systemic agents and
biologicals and showing a cost increase at a considerable
higher rate than general inflation for almost all agents and
modalities [31]. However, all-encompassing cost analyses also
including indirect costs are rare. Moreover, only few studies
comprise inpatients, as this alternative is rather uncommon in
many Western countries. We here provide a comprehensive
cost analysis of all important costs categories and all available
treatment alternatives in form of a bottom-up study with a
separate view on inpatient and outpatient therapy.
Comparison with other cost analyses
A few respective analyses also including inpatients have
been performed in Germany [21,20,22,23; Table S2]. However,
none of them comprised patients treated with biologicals, as
data were collected before the broad introduction of these
agents. The mean total annual costs determined in the German
studies by Sohn et al. [23] and Schöffski et al. [22] were slightly
lower compared to our study (7,092 € in our study versus 6,709
or 6,707 €, respectively; Table S2). This is mainly attributable
to slightly higher costs for inpatient treatment and somewhat
higher indirect costs noted in our study. 40.8% of our patients,
but only 28.3% of the patients analyzed in the two other studies
were hospitalized in the observation period, but the average
total hospitalization time was considerably shorter in our
collective (27.9 versus 39.1 days). Considering that our
collective comprised patients on biologicals and the other
collective did not, it is remarkable that costs for outpatient
medication were similar. However, the number of patients on
biologicals included in our study was low (n=8) and these
therapies were only prescribed for an average of four months
during the assessment period.
In another German multicenter study by Berger and
colleagues [20] total annual costs were remarkably lower
(2,866 €; Table S2), mostly due to lower direct medical costs.
This may be explained by the study population investigated
and by the study design since (a) only a very low percentage of
the patients (2.6%) were hospitalized and (b) data were
collected only for 3 months retrospectively and 6 weeks
prospectively and subsequently extrapolated to the year-
horizon.
Total costs, total direct medical costs and indirect costs due
to loss of working time were also assessed in a large US
American study by Fowler and colleagues, comprising 12,280
patients treated for psoriasis between 1998 and 2005 [32].
Cost levels were similar to those of our study, with the
exception of somewhat higher indirect costs, including
“disability payments” to be provided by the employer. However,
none of these reports explicitly compared in- and outpatient
Table 7. Regression analysis showing high impact of treatment mode on cost levels (n=112; n=8 patients treated with
biologicals excluded because of group size).
 Increase of costs [%]
 Inpatient therapy Phototherapy Classic systemic therapy
 (n=44) (n=49) (n=27)
Reference group Outpatient therapy Topical therapy
 (n=68) (n=36)
Direct medical costs 127,8*** 41,3** 60,3***
Outpatient medication costs -10,0 78,4** 103,9***
Costs for outpatient visits and diagnostics -31,6 30,8* 108,3***
Indirect costs through loss of working time 2,7 43,8** 7,3
Total costs 104,3*** 30,7* 44,1*
* p<0.05
** p<0.01
*** p<0.001
doi: 10.1371/journal.pone.0078152.t007
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therapy as separate options; neither does an Italian study form
the pre-biological era that comprises large numbers of
inpatients [25].
Costs of biological therapy
In contrast to phototherapy and classic systemic therapy,
costs for biologicals clearly exceeded costs for inpatient
treatment. This effect was appreciable from the descriptive
data, despite the small number of patients on biologicals that
prohibited statistical analysis for this subgroup. Our analysis is
likely to underestimate total actual costs of biological therapy,
as in the index years 2005 and 2006 most study patients just
started to take biologicals, which had been introduced in
Germany only shortly before (i.e. in autumn 2004). Patients
received these therapies for an average of only four months
within the assessment period. Today, there is a trend to long-
term therapy with biologicals with presumably higher direct
medical costs. Moreover, medication costs for most biologicals
have been rising considerably more than the general inflation
rate over the last years [31].
Also according to other recent studies, total costs increased
after introduction of biologicals, as the rise in medication costs
could not fully outweigh possible decreases in costs for
hospitalizations or outpatient admissions [21,26,31,34].
In a German study comparing inpatient treatment to
outpatient biological therapy with efalizumab, total annual costs
for the patient group receiving efalizumab were more than
threefold higher than for the inpatient group [21]. However, this
study might have underestimated follow-up costs after inpatient
treatment. Furthermore, efalizumab, now withdrawn from the
market, is known to be by far less effective than other
biologicals.
Fonia et al. [26] showed an increase of total annual health
care costs by £7,774 per patient after introduction of biologic
agents. Mean annual inpatient and outpatient admission costs
were hereby reduced by £1,682 whilst mean annual drug costs
increased by £9,456. Indirect costs were not examined.
In a study by Ghatnekar et al. [34] biologicals were used in
16% of the patients and accounted for 20% of the total costs,
whereas traditional systemic drugs (methothrexate, acitretin
and cyclosporine) were prescribed for 26% of the patients and
accounted for only 0.5% of total costs.
Only in the American study of Bhosle et al. [35], which was
conducted shortly after the introduction of biologicals total
health care costs did not differ significantly from the pre-
biologics period (14,662.22 US-$ versus 16,156.10 US-$;
p>0.05) despite a significant rise in prescription costs (33).
Overall, introduction of biologicals into the treatment of
psoriasis has led to a considerable raise in costs. However,
patients are significantly more satisfied and compliant with
biologicals than with other treatments [37]. Moreover, the
higher costs for biologicals also might outweigh long-term
health care costs of psoriasis patients, as biologicals have
favourable effects on the long term course of psoriatic arthritis
and probably also beneficial effects on concomitant
cardiovascular diseases.
Role of inpatient treatment
Our study demonstrates impressively that costs for inpatient
therapy exceed costs for all conventional outpatient
alternatives by far. Remarkably, former inpatients also required
high expenses for outpatient follow-up treatments, with 55%
needing additional phototherapy, 35% classic systemic therapy
and 10% biologicals. According to our data inpatient therapy
may still be less expensive than biological therapy. However,
inpatient treatment with dithranol and UV light cannot substitute
for biological treatment, as the effect of inpatient treatment only
had a considerably short duration of less than four months. As
a consequence, several inpatients of our cohort were
prescribed biologicals after demission. Our primary hypothesis
that time- and cost-intense inpatient treatment might lead to
long term remission of psoriasis and therefore to decreased
follow-up costs had to be rejected.
The enormous costs produced by inpatient therapy may in
part be justified by the fact that inpatients were more severely
affected than mere outpatients, with higher PASI scores and
higher prevalence of psoriatic arthritis and comorbidities (Table
2). It was recently shown that comorbidities are associated with
significantly higher hospitalization rates, outpatient visits and
total costs [33].
Willingness of patients to be hospitalized is decreasing as
effective and well-tolerated outpatient treatment options are
becoming accessible. In a recent study analysing patient
preferences for psoriasis treatments it was shown that patients
attach great value to outpatient treatment [36]. The trend
towards long-term outpatient treatment will continue, and
further highly efficient biological treatments such as, e.g.,
interleukin-17 antagonists are expected to become available in
the near future. Nevertheless, inpatient treatment will probably
retain its role for management of psoriasis patients with
multiple comorbidities and/or with acute exacerbation.
Strengths and limitations
Our study has several limitations. As data were collected
shortly after the introduction of biologicals into the German
market, the subgroup of patients receiving biologicals was too
small to explicitly compare costs for outpatient biological
therapy to inpatient therapy with appropriate statistical
methods. Our cost data stem from 2005/2006. Since then the
price of etanercept slightly decreased by 2-3%, whereas the
price for infliximab increased by 8-19%. In addition, some of
the most efficient biologicals, i.e. adalimumab and
ustekinumab, were not available at the time of data collection.
Our study was conducted as a monocentric cost analysis,
impairing generalization of our results. Moreover, direct
comparison of inpatient and outpatient costs is hampered by
the fact that inpatients were more severely affected than
outpatients and presented higher PASI scores, higher
prevalence of psoriatic arthritis and higher rates of
comorbidities.
The well-known human capital approach was used for
measuring indirect costs, as it allowed the inclusion of the
societal value of honorary activities. With regard to the high
proportion of unemployment within our study collective (40%)
that approach seemed to estimate indirect costs in the most
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appropriate way. Nevertheless this approach tends to
overestimate opportunity costs in the long run, why a
supplement by e.g. a friction cost approach could have been
reasonable.
A major strength of our study is that it provides the first all-
encompassing cost analysis including all available treatment
modalities. Our analysis reflects the real-world cost situation, in
which prescription of combination regimens is frequent. Costs
have been collected not only by chart review, allowing detailed
calculation of direct medical costs, but also in personal
interviews, which provided precise information on individual
costs and indirect costs.
Conclusion
Our study shows that the costs of inpatient therapy are
significantly higher than those of outpatient treatment. Inpatient
treatment did not result in decreased follow-up costs, as the
duration of remission was relatively short and several patients
required systemic treatment after demission. Patients receiving
biologicals produced the overall highest costs. Topical
treatment, phototherapy or classic systemic medications were
significantly less costly when prescribed in an outpatient
setting, as expected. Mere outpatient treatment with classic
systemic anti-psoriatic medications turned out to be less cost-
intense than phototherapy. Despite high requirements for
laboratory testing and monitoring for adverse effects, this
option is attractive from the economic perspective.
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